Patient Safety & Site of Service for Biologics Although emphasizing its strong support for the use of biologic agents as necessary treatments for rheumatic diseases, the ACR Board of Directors continues to be concerned about the safe delivery of these agents, given the potential for associated adverse events and infusion reactions. In a position statement…
Mary Beth Nierengarten is a writer, editor and journalist with over 25 years of medical communications experience. She is a regular contributor to a number of online and print publications and writes in most clinical areas, as well as on health policy and economic issues. She lives in Minneapolis and can be reached at [email protected].
Articles by Mary Beth Nierengarten
Quality Update Reporting Changes under MACRA
With the termination of the Sustainable Growth Rate formula through the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA), clinicians who participate in Medicare Part B will now be reimbursed through a new payment model called the Quality Payment Program (QPP). How It Works The QPP rewards the delivery of high-quality patient care via…
Can Genetic Information Change the Clinical Care of Rheumatology Patients?
WASHINGTON, D.C.—Calling it an extremely challenging topic, Peter K. Gregersen, MD, professor and head, Robert S. Boas Center for Genomics and Human Genetics, Feinstein Institute, Manhasset, N.Y., said the current role of genetics in clinical practice is less about how to use genetic information to care for patients and more about how providers and patients…
Rheumatology Research Abstracts Highlight Treatment for Hand OA, Risk of Depression in Lupus and More
WASHINGTON, D.C.—What do treating hand osteoarthritis (OA) in the primary care setting, high financial strain and risk of depression in patients with lupus, prolonged sitting and cardiovascular disease, and sex-specific treatment after total hip arthroplasty have in common? They were all topics presented during a session titled ARHP I: Exemplary Abstracts at the 2016 ACR/ARHP…
Baricitinib Effective for Treating Refractory Rheumatoid Arthritis
Soon, rheumatologists may have another drug to offer their patients with refractory rheumatoid arthritis (RRA) for whom effective and safe treatment remains challenging. A study published in the New England Journal of Medicine shows that patients with RRA treated with once-daily baricitinib in a 4 mg dose had a significant clinical improvement in symptoms of…
Former Senator Tim Hutchinson Urges ACR Members to Advocate for Rheumatology on Local, State and Federal Levels
WASHINGTON, D.C.—“Regardless of where we are on the political spectrum, we have to get engaged,” said Sen. Tim Hutchinson, senior director, Greenberg Traurig LLP, Washington, D.C., speaking at the 2016 ACR/ARHP Annual Meeting. As a former U.S. senator from Arkansas, Sen. Hutchinson talked about the importance of members in such organizations as the ACR to…
Biomedical Research Key to Advancing Clinical Care for Rheumatic Diseases
WASHINGTON, D.C.—The importance of biomedical research to advancing clinical care with the ultimate goal of improving patients’ lives was on display during an ACR Discovery 2016 plenary session at the 2016 ACR/ARHP Annual Meeting. The session offered new ways to think about and treat select rheumatologic diseases, including research showing for the first time the…
Mesenchymal Stem Cell Therapy May Help Slow, Repair Degenerative Signs of Osteoarthritis, Musculoskeletal Disease
WASHINGTON, D.C.—For patients with osteoarthritis and other age-related musculoskeletal diseases, treatment with mesenchymal stem cells may soon offer a potent way to slow and repair degenerative signs of disease. This is the goal, a goal that is moving from the laboratory to the clinic as results from ongoing randomized clinical trials show the safety and…
The ACR Government Affairs Committee’s Outgoing Chair Urges Members to Continue Advocating for Rheumatology
WASHINGTON, D.C.—Although political polarization in the U.S. has affected many people’s interest in participating in legislative and advocacy efforts that promote their concerns, William Harvey, MD, MSc, the ACR’s (immediate past) chair of the Government Affairs Committee, encouraged rheumatologists and ACR/ARHP members to remain engaged and get involved with the ACR to fight for issues…
Insurance Subcommittee to the Rescue
Concerned about reimbursement for specialty drugs? Wondering if your patient can continue on a prescribed medication despite formulary changes? Unsure how to request a tier exception? No need to face these issues alone. The ACR has a resource that can assist with questions regarding coverage and payment policies for private insurers and Medicare. That resource…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 16
- Next Page »